Browse By: Country ι Category ι Latest Reports ι Tag
Home  »  Global Markets Direct

Global Markets Direct Market Research Reports

Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials.

At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.

Fate Therapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Fate Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Fate Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Fate Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using da
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
LegoChem Biosciences, Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘LegoChem Biosciences, Inc - Product Pipeline Review - 2016’, provides an overview of the LegoChem Biosciences, Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by LegoChem Biosciences, Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built us
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
3SBio Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘3SBio Inc. - Product Pipeline Review - 2016’, provides an overview of the 3SBio Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by 3SBio Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
Addex Therapeutics Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Addex Therapeutics Ltd - Product Pipeline Review - 2016’, provides an overview of the Addex Therapeutics Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Addex Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
GTx, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘GTx, Inc. - Product Pipeline Review - 2016’, provides an overview of the GTx, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by GTx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Mar
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
SK Chemicals Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘SK Chemicals Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the SK Chemicals Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by SK Chemicals Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
UAB Profarma - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘UAB Profarma - Product Pipeline Review - 2016’, provides an overview of the UAB Profarma’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by UAB Profarma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from G
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
Yuhan Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Yuhan Corporation - Product Pipeline Review - 2016’, provides an overview of the Yuhan Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Yuhan Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information
Published Date: May 2016
Published By: Global Markets Direct

Price: $1500
Stroke - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Stroke - Pipeline Review, H1 2016’, provides an overview of the Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy a
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Myelodysplastic Syndrome - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Myelodysplastic Syndrome - Pipeline Review, H1 2016’, provides an overview of the Myelodysplastic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. Global Markets Direct’s report fea
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Metastatic Colorectal Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Metastatic Colorectal Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Colorectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects. Global Markets Direc
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Small-Cell Lung Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Small-Cell Lung Cancer - Pipeline Review, H1 2016’, provides an overview of the Small-Cell Lung Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. Global Markets Direct’s report features in
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Cervical Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cervical Cancer - Pipeline Review, H1 2016’, provides an overview of the Cervical Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from acr
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Neuroblastoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Neuroblastoma - Pipeline Review, H1 2016’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chroni
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Follicular Lymphoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Follicular Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Follicular Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Epithelial Ovarian Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Epithelial Ovarian Cancer - Pipeline Review, H1 2016’, provides an overview of the Epithelial Ovarian Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Ebola Viral Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Ebola Viral Infections - Pipeline Review, H1 2016’, provides an overview of the Ebola Viral Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebola Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebola Viral Infections and features dormant and discontinued projects. Global Markets Direct’s report features in
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016’, provides an overview of the Refractory Acute Myeloid Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects.
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Spinal Cord Injury - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Spinal Cord Injury - Pipeline Review, H1 2016’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. Global Markets Direct’s report features investigational dr
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016’, provides an overview of the H5N1 Infection (Avian Influenza) pipeline landscape. The report provides comprehensive information on the therapeutics under development for H5N1 Infection (Avian Influenza), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H5N1 Infection (Avian Influenza) and features dormant and discontinued projects. Glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Migraine - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Migraine - Pipeline Review, H1 2016’, provides an overview of the Migraine pipeline landscape. The report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Hypercholesterolemia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hypercholesterolemia - Pipeline Review, H1 2016’, provides an overview of the Hypercholesterolemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Escherichia coli Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Escherichia coli Infections - Pipeline Review, H1 2016’, provides an overview of the Escherichia coli Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. Global Markets Direct’
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Hemophilia A - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hemophilia A - Pipeline Review, H1 2016’, provides an overview of the Hemophilia A pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Cancer Pain - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cancer Pain - Pipeline Review, H1 2016’, provides an overview of the Cancer Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Diabetic Foot Ulcers - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Diabetic Foot Ulcers - Pipeline Review, H1 2016’, provides an overview of the Diabetic Foot Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Gingivitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Gingivitis - Pipeline Review, H1 2016’, provides an overview of the Gingivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gingivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gingivitis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering o
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Osteonecrosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Osteonecrosis - Pipeline Review, H1 2016’, provides an overview of the Osteonecrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteonecrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Melasma (Chlosma) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Melasma (Chlosma) - Pipeline Review, H1 2016’, provides an overview of the Melasma (Chlosma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Melasma (Chlosma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Gastritis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Gastritis - Pipeline Review, H1 2016’, provides an overview of the Gastritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Peritonitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Peritonitis - Pipeline Review, H1 2016’, provides an overview of the Peritonitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peritonitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Achromatopsia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Achromatopsia - Pipeline Review, H1 2016’, provides an overview of the Achromatopsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Achromatopsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Achromatopsia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016’, provides an overview of the Porphyria (Erythropoietic Protoporphyri) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant a
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Hyperoxaluria - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hyperoxaluria - Pipeline Review, H1 2016’, provides an overview of the Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Hypothyroidism - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hypothyroidism - Pipeline Review, H1 2016’, provides an overview of the Hypothyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypothyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Anaphylaxis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Anaphylaxis - Pipeline Review, H1 2016’, provides an overview of the Anaphylaxis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Q Fever - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Q Fever - Pipeline Review, H1 2016’, provides an overview of the Q Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Q Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 thera
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Impetigo - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Impetigo - Pipeline Review, H1 2016’, provides an overview of the Impetigo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Pigmented Villonodular Synovitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Pigmented Villonodular Synovitis - Pipeline Review, H1 2016’, provides an overview of the Pigmented Villonodular Synovitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. Glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Gallbladder Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Gallbladder Cancer - Pipeline Review, H1 2016’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational dr
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Vaginal Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Vaginal Cancer - Pipeline Review, H1 2016’, provides an overview of the Vaginal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H1 2016’, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontin
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Obstructive Sleep Apnea - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Obstructive Sleep Apnea - Pipeline Review, H1 2016’, provides an overview of the Obstructive Sleep Apnea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. Global Markets Direct’s report feature
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016’, provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted pipeline therapeutics. The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press rele
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2016’, provides in depth analysis on Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted pipeline therapeutics. The report provides comprehensive information on the Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted pipeline therapeutics. The report provides comprehensive information on the Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Or
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) - Pipeline Review, H1 2016’, provides in depth analysis on Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2) targeted pipeline therapeutics. The report provides comprehensive information on the Substance-K Receptor (SKR or NK-2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or TACR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest n
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016’, provides in depth analysis on N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted pipeline therapeutics. The report provides comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report a
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted pipeline therapeutics. The report provides comprehensive information on the Somatostatin Receptor Type 2 (SRIF-1 or SSTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics de
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Revie
Summary Global Markets Direct’s, ‘Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016’, provides in depth analysis on Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted pipeline therapeutics. The report provides comprehensive information on the Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfam
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016’, provides in depth analysis on Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted pipeline therapeutics. The report provides comprehensive information on the Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC), targeted therapeutics, complete with analysis
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Review, H1 2016’, provides in depth analysis on Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted pipeline therapeutics. The report provides comprehensive information on the Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016’, provides in depth analysis on Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted pipeline therapeutics. The report provides comprehensive information on the Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therape
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016’, provides in depth analysis on Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted pipeline therapeutics. The report provides comprehensive information on the Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press r
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016’, provides in depth analysis on Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted pipeline therapeutics. The report provides comprehensive information on the Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016’, provides in depth analysis on Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted pipeline therapeutics. The report provides comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of t
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016’, provides in depth analysis on Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted pipeline therapeutics. The report provides comprehensive information on the Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provi
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016’, provides in depth analysis on Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted pipeline therapeutics. The report provides comprehensive information on the Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of ke
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Glucosylceramidase (Acid Beta-Glucosidase or Alglucerase or D-Glucosyl-N-Acylsphingosine Glucohydrolase or EC 3.2.1.45) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Glucosylceramidase (Acid Beta-Glucosidase or Alglucerase or D-Glucosyl-N-Acylsphingosine Glucohydrolase or EC 3.2.1.45) - Pipeline Review, H1 2016’, provides in depth analysis on Glucosylceramidase (Acid Beta-Glucosidase or Alglucerase or D-Glucosyl-N-Acylsphingosine Glucohydrolase or EC 3.2.1.45) targeted pipeline therapeutics. The report provides comprehensive information on the Glucosylceramidase (Acid Beta-Glucosidase or Alglucerase or D-Glucosyl-N-Acylsphingosine Glucohydrolase or EC 3.2.1.45), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its com
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Review, H1 2016’, provides in depth analysis on Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted pipeline therapeutics. The report provides comprehensive information on the Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heparanase (Endo-Glu
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Alpha-Galactosidase A (Alpha-D-Galactosidase A or Alpha-D-Galactoside Galactohydrolase or Melibiase or EC 3.2.1.22) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Alpha-Galactosidase A (Alpha-D-Galactosidase A or Alpha-D-Galactoside Galactohydrolase or Melibiase or EC 3.2.1.22) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-Galactosidase A (Alpha-D-Galactosidase A or Alpha-D-Galactoside Galactohydrolase or Melibiase or EC 3.2.1.22) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha-Galactosidase A (Alpha-D-Galactosidase A or Alpha-D-Galactoside Galactohydrolase or Melibiase or EC 3.2.1.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete resear
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Pipeline Review, H1 2016’, provides in depth analysis on Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) targeted pipeline therapeutics. The report provides comprehensive information on the Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete resear
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2016’, provides in depth analysis on Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted pipeline therapeutics. The report provides comprehensive information on the Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted pipeline therapeutics. The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therap
Published Date: May 2016
Published By: Global Markets Direct

Price: $3500
Malaria - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Malaria - Pipeline Review, H1 2016’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 thera
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Tuberculosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H1 2016’, provides an overview of the Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Renal Cell Carcinoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Renal Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Renal Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Diffuse Large B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. Global Markets D
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and fe
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Psoriatic Arthritis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Psoriatic Arthritis - Pipeline Review, H1 2016’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Diabetic Retinopathy - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Diabetic Retinopathy - Pipeline Review, H1 2016’, provides an overview of the Diabetic Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Endometrial Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2016’, provides an overview of the Endometrial Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational dr
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Muscular Dystrophy - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Muscular Dystrophy - Pipeline Review, H1 2016’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. Global Markets Direct’s report features investigational dr
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and featur
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) an
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Thrombocytopenia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Thrombocytopenia - Pipeline Review, H1 2016’, provides an overview of the Thrombocytopenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016’, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Jun
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Malignant Pleural Mesothelioma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Pipeline Review, H1 2016’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. Global Marke
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Benign Prostatic Hyperplasia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Benign Prostatic Hyperplasia - Pipeline Review, H1 2016’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. Global Markets Direc
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued proj
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Gouty Arthritis (Gout) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Pipeline Review, H1 2016’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. Global Markets Direct’s report features in
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therape
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Aspergillosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Aspergillosis - Pipeline Review, H1 2016’, provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued proj
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016’, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Entero
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Diabetic Neuropathy - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Diabetic Neuropathy - Pipeline Review, H1 2016’, provides an overview of the Diabetic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Ewing Sarcoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Ewing Sarcoma - Pipeline Review, H1 2016’, provides an overview of the Ewing Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Critical Limb Ischemia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H1 2016’, provides an overview of the Critical Limb Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. Global Markets Direct’s report features in
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Irritable Bowel Syndrome - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Irritable Bowel Syndrome - Pipeline Review, H1 2016’, provides an overview of the Irritable Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. Global Markets Direct’s report fea
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Diphtheria - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Diphtheria - Pipeline Review, H1 2016’, provides an overview of the Diphtheria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diphtheria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering o
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Systemic Mastocytosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Systemic Mastocytosis - Pipeline Review, H1 2016’, provides an overview of the Systemic Mastocytosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. Global Markets Direct’s report features invest
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. Global Markets D
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Pemphigus Vulgaris - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Pemphigus Vulgaris - Pipeline Review, H1 2016’, provides an overview of the Pemphigus Vulgaris pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. Global Markets Direct’s report features investigational dr
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Cryptosporidiosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cryptosporidiosis - Pipeline Review, H1 2016’, provides an overview of the Cryptosporidiosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cryptosporidiosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000
Chondrosarcoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Chondrosarcoma - Pipeline Review, H1 2016’, provides an overview of the Chondrosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000